



Supplementary Figure 1, related to Figure 3

(A-C) Analysis of Pimonidazole in apCAFs, iCAFs and myCAFs from PDAC tumors. (A) Gating for Ly6C and MHC-II in CD31-CD45-EpCAM-PDPN⁺ cells. (B) Histogram of fluorescence intensity and (C) quantification of Pimonidazole median fluorescence intensity (MFI) comparing apCAFs, iCAFs and myCAFs. N=3 mice. P-values were calculated by matched one-way ANOVA. (D) Gene Set Enrichment Analysis (GSEA) of selected hallmark signatures comparing inflammatory CAFs (iCAFs) and antigen-presenting CAFs (apCAFs) based on single-cell RNA-sequencing (scRNA-seq) data from murine PDAC. Data from (5). (E) qPCR for the indicated transcripts in KPC pancreatic cancer cells, and two independently isolated PSC lines used in this study. wt = wildtype. N=3 biological replicates. (F) GSEA comparing PSCs cultured in normoxia (20% O₂) or hypoxia (0.5% O₂) for 48h. myCAF signature derived from (4). N=3 biological replicates.